S01E12 HYPERION: Sotatercept in Early PAH

In this episode of PRISM Rounds, we review “Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis,” published in the New England Journal of Medicine (published online September 30, 2025; issue October 23, 2025). We break down the phase 3 HYPERION trial in newly diagnosed PAH on background double/triple therapy, focusing on the primary composite endpoint of clinical worsening, the interpretation challenges created by early trial termination, and the safety signals clinicians should anticipate (notably epistaxis and telangiectasia). Educational use only — not medical advice.Article (PubMed): https://pubmed.ncbi.nlm.nih.gov/41025556/NEJM landing page: https://www.nejm.org/doi/full/10.1056/NEJMoa2508170Trial registration: https://clinicaltrials.gov/study/NCT04811092TagsPulmonary Arterial Hypertension, PAH, Pulmonary Hypertension, Critical Care, Pulmonary Medicine, Cardiology, Journal Club, NEJM, Clinical Trials, Randomized Trial, HYPERION, Sotatercept, Right Heart Failure, 6-Minute Walk, NT-proBNP, Risk Stratification, REVEAL Lite 2, COMPERA 2.0, Pharmacotherapy, Evidence-Based Medicine